Results for ranibizumab translation from Slovak to English

povolený ranibizumab
ranibizumab allowed

skupina i ranibizumab 0,5 mg
group i ranibizumab

obsahuje liečivo nazvané ranibizumab.
it contains the active substance called ranibizumab.

ranibizumab 0,5 mg pri prn n=117
0.5 mg n=117

ranibizumab 0,5 mg + laser n=118
0.5 mg + laser n=118

liečivo je ranibizumab (10 mg/ml).
the active substance is ranibizumab (10 mg/ml).

lucentis 10 mg/ml injekčný roztok ranibizumab
lucentis 10 mg/ml solution for injection ranibizumab

predtým ranibizumab 0,5 mg + laser n=83
0.5 mg + laser n=83

lucentis je liek, ktorý obsahuje účinnú látku ranibizumab.
lucentis is a medicine that contains the active substance ranibizumab.

- liečivo v lucentise je ranibizumab (10 mg/ ml).
- the active substance in lucentis is ranibizumab (10 mg/ ml).

lucentis 10 mg/ ml injekčný roztok ranibizumab na intravitreálne použitie
lucentis 10 mg/ ml solution for injection ranibizumab intravitreal use

lucentis 10 mg/ml injekčný roztok v naplnenej injekčnej striekačke ranibizumab
lucentis 10 mg/ml solution for injection in pre-filled syringe ranibizumab

Účinná látka lieku lucentis, ranibizumab, je malý fragment monoklonálnej protilátky.
the active substance in lucentis, ranibizumab, is a small piece of a monoclonal antibody.

ranibizumab blokovaním tohto faktora zmierňuje rast krvných ciev a reguluje presakovanie a opuch.
by blocking this factor, ranibizumab reduces the growth of the blood vessels and controls the leakage and swelling.

ranibizumab je fragment humanizovanej monoklonálnej protilátky vytvorenej v bunkách escherichia coli rekombinantnou dna technológiou.
ranibizumab is a humanised monoclonal antibody fragment produced in escherichia coli cells by recombinant dna technology.

preto sa ranibizumab nemá používať v gravidite, pokiaľ očakávaný prínos nie je väčší ako možné riziko pre plod.
therefore, ranibizumab should not be used during pregnancy unless the expected benefit outweighs the potential risk to the foetus.

skupina iii - ranibizumab 0,5 mg/pdt verteporfínom od 3. mesiaca (n=55)
ranibizumab 0.5 mg/verteporfin pdt group iii from month 3 onwards (n=55)

ak ste alergický na ranibizumab alebo na ktorúkoľvek z ďalších zložiek tohto lieku (uvedených v časti 6).
if you are allergic to ranibizumab or any of the other ingredients of this medicine (listed in section 6).

výbor chmp konštatoval, že pri vlhkej forme amd bol liek eylea rovnako účinný ako ranibizumab z hľadiska zachovania zrakovej ostrosti pacientov po prvom roku liečby.
the chmp noted that for wet amd eylea was as effective as ranibizumab in maintaining patients’ vision after the first year of treatment.

ranibizumab bol navrhnutý tak, aby blokoval látku nazývanú cievny endotelový rastový faktor a (vegf-a).
ranibizumab has been designed to block a substance called vascular endothelial growth factor a (vegf-a).